Cargando…
Evaluating the efficacy and safety of single-agent etoposide intra-CSF chemotherapy in children and young people with relapsed/refractory central nervous system tumours
PURPOSE: The aim of the project was to evaluate intra-CSF etoposide administration in a palliative setting for children and young people with relapsed/refractory central nervous system (CNS) tumours, with the primary endpoints being overall survival and progression-free survival time. A safety endpo...
Autores principales: | Butler, Anna, Meijer, Lisethe, Liu, Jo-Fen, Chohan, Manjit, Jalloh, Ibrahim, Macarthur, Donald, Parr, Margaret, Wilne, Sophie, Wilson, Shaun, Walker, David, Grundy, Richard, Dandapani, Madhumita |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10227148/ https://www.ncbi.nlm.nih.gov/pubmed/36949251 http://dx.doi.org/10.1007/s00381-023-05872-w |
Ejemplares similares
-
Phase II study of intravenous etoposide in patients with relapsed ependymoma (CNS 2001 04)
por: Apps, John R, et al.
Publicado: (2022) -
Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma
por: Imaya, Masayuki, et al.
Publicado: (2022) -
Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL
por: Torka, Pallawi, et al.
Publicado: (2022) -
Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma
por: Mehrzad, Valiollah, et al.
Publicado: (2017) -
RARE-03 CENTRAL NERVOUS SYSTEM TUMORS IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1, A COHORT FROM A NATIONAL PEDIATRIC ONCOLOGY CENTER
por: Vandenput, Kim, et al.
Publicado: (2021)